First, because mot‐2 is a central player in both the p53 pathway (Gestl and Anne Bottger, 2012) and epithelial–mesenchymal transition (EMT) (Na et al., 2016) and it can simultaneously affect various biological processes including tumorigenesis, invasion, and metastasis, this current study is unique in presenting a potential therapeutic role for UBXN2A/CHIP in the regulation of some or all of the above fundamental biological events altered by mot‐2 in cancer cells. The gene discussed is HSPA9; the disease is cancer.